| Date Filed | Type | Description |
| 10/05/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 08/10/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/10/2023 |
8-K
| Quarterly results |
| 07/21/2023 |
8-K
| Quarterly results |
| 07/13/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 07/11/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 06/29/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data|
Docs:
|
"Exhibit 99.1 ImmuCell Announces Change in Timing of Anticipated FDA Submission PORTLAND, Maine, June 28, 2023 -- ImmuCell Corporation , a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced a change to its anticipated FDA submission schedule. “Although we had planned to make our next FDA submission during the second quarter of this year, we have decided to add one additional month to the projected regulatory development process for Re-Tain,” commented Michael F. Brigham, President and CEO of ImmuCell. “The CMC Technical Section is ready for submission at this time, but we are going to use this extra time to optimize our readiness for the related ..." |
|
| 05/11/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 04/28/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/28/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/18/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 04/05/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 03/29/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 02/28/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 02/01/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 01/09/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
| 11/21/2022 |
8-K
| Quarterly results |
| 11/21/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/21/2022 |
10-Q/A
| Quarterly Report for the period ended June 30, 2022 [amend] |
| 11/21/2022 |
10-Q/A
| Quarterly Report for the period ended March 31, 2022 [amend] |
| 11/10/2022 |
8-K
| Quarterly results |
| 11/10/2022 |
NT 10-Q
| Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB: |
| 10/05/2022 |
8-K
| Quarterly results |
| 08/17/2022 |
8-K
| Quarterly results |
| 08/11/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 08/11/2022 |
8-K
| Quarterly results |
| 07/27/2022 |
8-K
| Quarterly results |
| 07/06/2022 |
8-K
| Quarterly results |
| 06/21/2022 |
8-K/A
| Quarterly results |
| 06/16/2022 |
8-K
| Quarterly results |
| 05/12/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
| 05/12/2022 |
8-K
| Quarterly results |
| 04/28/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
|